Lv3
210 积分 2021-12-09 加入
New promises and challenges in the treatment of advanced non-small-cell lung cancer
5天前
已完结
Olfactory sensory experience regulates gliomagenesis via neuronal IGF1
2个月前
已完结
Therapy for Stage IV Non-Small Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline, Version 2025.1
2个月前
已完结
Amivantamab plus Lazertinib in Previously Untreated EGFR -Mutated Advanced NSCLC
2个月前
已完结
First-line zorifertinib for EGFR-mutant non-small cell lung cancer with central nervous system metastases: The phase 3 EVEREST trial
3个月前
已完结
Efficacy and safety of immune checkpoint inhibitors for individuals with advanced EGFR-mutated non-small-cell lung cancer who progressed on EGFR tyrosine-kinase inhibitors: a systematic review, meta-analysis, and network meta-analysis
3个月前
已完结
Efficacy and safety of immune checkpoint inhibitors for individuals with advanced EGFR-mutated non-small-cell lung cancer who progressed on EGFR tyrosine-kinase inhibitors: a systematic review, meta-analysis, and network meta-analysis
3个月前
已完结
CNS Response to Osimertinib Versus Standard Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients With Untreated EGFR-Mutated Advanced Non–Small-Cell Lung Cancer
3个月前
已完结
[Survey on the standardization of Lung Cancer Diagnosis and Treatment in Pulmonary and Critical Care Medicine in China in 2024]
4个月前
已完结
Neoadjuvant Osimertinib for Resectable EGFR -Mutated Non-Small-Cell Lung Cancer
4个月前
已关闭
皖公网安备34019202002308
